4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy
Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms....To view the full article, register now.
Already a subscriber? Click here to view full article